NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

MTA Bisphosphonates for treating osteoporosis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

# Final appraisal determination

(when no ACD was issued)

|  |
| --- |
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| It was raised during the scoping process that some groups will have difficulty adhering to the complex instructions for taking oral bisphosphonates and their benefit from these treatments may be compromised.  The committee has taken this into consideration. |

|  |
| --- |
| 1. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No |

|  |
| --- |
| 1. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No |

|  |
| --- |
| 1. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| Some groups may have difficulty adhering to the complex instructions for taking oral bisphosphonates. |

|  |
| --- |
| 1. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| Some groups may have difficulty adhering to the complex instructions for taking oral bisphosphonates. |

|  |
| --- |
| 1. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE’s obligations to promote equality? |
| The committee considered appropriate to consider the cost effectiveness of intravenous bisphosphonates in people who could not tolerate oral preparations of bisphosphonates and in whom no active treatment would be the most relevant comparator. The committee concluded that intravenous bisphosphonates would be cost effective in this group and recommended intravenous bisphosphonates for those who have difficulty taking oral bisphosphonates or if these drugs are contraindicated or not tolerated. |

|  |
| --- |
| 1. Have the committee’s considerations of equality issues been described in the final appraisal determination, and, if so, where? |
| Yes, equality issues are described in the final appraisal determination (section 4.2 and 4.24) |

**Approved by Associate Director (name):** …Melinda Goodall…………………………………

**Date:** 16/06/2017